Below is a list with tagged columns and company profiles.

Today's Headlines Pharmaceutical Industry

  • Pharmaceutical Industry: B. Braun Indonesia Opens Factory

    Pharmaceutical Industry: B. Braun Indonesia Opens Factory

    B. Braun Indonesia, the local unit of the German medical and pharmaceutical device company, held the opening ceremony for its factory on Thursday (27/07). This new factory, expected to be fully operational in 2018, is the company's first infusion solutions factory in Indonesia. The move implies that B. Braun Indonesia expanded its business activities from merely being a distributor to becoming both distributor and manufacturer of infusion and injectable medicines in Indonesia.

    Read more ›

  • Pharmaceutical Industry Indonesia: Is 10% Growth Possible in 2017?

    Pharmaceutical Industry Indonesia: Is 10% Growth Possible in 2017?

    Indonesia's pharmaceutical industry remains promising for foreign investors, evidenced by rising growth in the first half of the year. For the first time in three years growth in Indonesia's pharmaceutical industry could touch double-digit figures again. Parulian Simanjuntak, Executive Director of the International Pharmaceutical Manufacturers Group (IPMG), said the industry has improved compared to the situation one year ago.

    Read more ›

  • Kalbe Farma to Produce Erythropoietin (EPO) for Indonesia

    Kalbe Farma to Produce Erythropoietin (EPO) for Indonesia

    Kalbe Farma, Indonesia's largest pharmaceutical company, is set to start marketing its erythropoietin product (also known as EPO) domestically. Starting from mid-2018 Kalbe Farma will produce EPO, one of the raw materials for the production of medicines to treat cancer and kidney disease. The pharmaceutical company will become the first publicly listed company on the Indonesia Stock Exchange that produces EPO.

    Read more ›

  • Pharmaceutical Industry Indonesia: Still Lucrative Business?

    Pharmaceutical Industry Indonesia: Still Lucrative Business?

    Indonesia's pharmaceutical market will be worth USD $5.8 billion in 2017, up 5-6 percent (y/y) from the preceding year. Growth is attributed to Indonesia's universal health care program (Jaminan Kesehatan Nasional, or JKN) that was launched in 2014. As such, Indonesia's pharmaceutical industry still has great potential, says Parulian Simanjuntak, Executive Director at the International Pharmaceutical Manufacturers' Group (IPMG).

    Read more ›

  • Foreign Investment in Indonesia's Pharmaceutical Industry

    Foreign Investment in Indonesia's Pharmaceutical Industry

    Foreign pharmaceutical companies have already invested more than USD $1 billion in Indonesia over the past couple of years. These investments involves 34 companies that are all members of the International Pharmaceutical Manufacturers Group (IPMG). Parulian Simanjuntak, IPMG Executive Director, informed that these investments have been conducted not only to establish new factories but also for other forms of business expansion as well as marketing. It is estimated that 205 pharmaceutical companies are competing for market share in Indonesia.

    Read more ›

  • Developing a Self-Sufficient Pharmaceutical Industry in Indonesia

    Developing a Self-Sufficient Pharmaceutical Industry in Indonesia

    Indonesian President Joko Widodo signed Presidential Instruction No. 6/2016 on the Acceleration of Development of the Pharmaceutical Industry and Medical Devices on 8 June 2016. Through this instruction Widodo calls on all relevant ministries - including the Health Ministry, Industry Ministry and Finance Ministry - to take efforts to boost development of Indonesia's pharmaceutical industry. The Health Industry has a key task to write an action plan for the development of a self-sufficient pharmaceutical industry and to boost competitiveness.

    Read more ›

  • 11th Stimulus Package: Pharmaceutical Industry of Indonesia

    11th Stimulus Package: Pharmaceutical Industry of Indonesia

    For its raw materials the pharmaceutical industry of Indonesia is highly dependent on imports. Around 90 percent of medicines' raw materials, roughly IDR 7 trillion (approx. USD $526 million), may be imported this year. Meanwhile, given the Indonesian government is eager to develop its universal health care program (launched in 2014), demand for pharmaceutical products in Indonesia is expected to rise further. Total clients under the national health insurance program is expected to rise from 162 million in 2015 to 186 million in 2016. By the year 2019 the government wants to provide universal health care to all Indonesians.

    Read more ›

  • Indonesia Unveils 11th Economic Stimulus Package: a Quick Look

    Indonesia Unveils 11th Economic Stimulus Package: a Quick Look

    The government of Indonesia unveiled its eleventh economic stimulus package. The country's Chief Economics Minister Darmin Nasution presented the package at the State Palace in Jakarta on Tuesday (29/03). Indonesia's latest stimulus package includes a lower tax rate on property purchased by local real estate investment trusts, the harmonization of customs checks across the nation's ports (curtailing dwell time), government subsidies for loans taken up Indonesia's export-oriented small and medium enterprises, and the drawing of a roadmap for the nation's pharmaceutical industry.

    Read more ›

  • Pharmaceutical Firm Kalbe Farma Facing Macroeconomic Headwinds

    Pharmaceutical Firm Kalbe Farma Facing Macroeconomic Headwinds

    Indonesia's largest pharmaceutical company, Kalbe Farma, felt the impact of macroeconomic headwinds. The company, one of the largest public pharmaceutical companies in Southeast Asia, today announced its indicative performance (unaudited) for the year 2015. While its net sales grew 3 percent year-on-year (y/y) to IDR 17.4 trillion (approx. USD $1.3 billion), the company's net income fell 4.3 percent (y/y) to IDR 1.98 trillion (approx. USD $147 million). Kalbe Farma's performance in 2015 was plagued by weaker purchasing power in Indonesia and the depreciated rupiah exchange rate.

    Read more ›

  • Healthcare Indonesia: Boosting Local Production of Medicines' Raw Materials

    Healthcare Indonesia: Boosting Local Production of Medicines' Raw Materials

    In one of the next economic stimulus packages of the Indonesian government the focus will be on increasing domestic production of raw materials for medicines and medical devices. Currently, these industries are still highly dependent on imports of raw materials. It is estimated that around 90 percent of raw/basic materials for medicines and medical devices need to be imported from abroad and therefore cause additional pressure on Indonesia's balance of payments.

    Read more ›

Latest Columns Pharmaceutical Industry

  • How Big Indonesian Pharmaceutical Firms Cope with Rupiah Weakness

    How the Big Indonesian Pharmaceutical Firms Cope with Rupiah Weakness

    One of the national industries that is heavily affected by the weak rupiah exchange rate is Indonesia's pharmaceutical industry. Considering around 90 percent of raw materials in the pharmaceutical industry need to be imported from abroad (in US dollars), production costs rise sharply in times of significant rupiah depreciation. It is estimated that materials imported from abroad account for about 75 percent of pharmaceutical companies' total production costs.

    Read more ›

  • Developing Upstream Facilities in Indonesia's Pharmaceutical Industry

    Developing Upstream Facilities in Indonesia's Pharmaceutical Industry

    Vincent Harijanto, Head of the Indonesian Pharmaceutical Association (GP Farmasi) business development committee, said about 95 percent of raw materials used in Indonesia's pharmaceutical industry need to be imported from abroad. This dependence on imports causes several problems, for example prices of pharmaceutical products are relatively high on the Indonesian market, while Indonesian pharmaceutical companies (and Indonesian consumers) can suddenly face rising prices in times of rupiah depreciation.

    Read more ›

  • Pharmaceutical Exports Indonesia Remain Under Pressure in 2017

    Pharmaceutical Exports Indonesia Remain Under Pressure in 2017

    Exports of pharmaceutical products from Indonesia have declined due to increasing competition from China on the international market. Chinese pharmaceutical companies dominate export markets supported by China's low production cost environment and the availability of raw materials at home. However, despite this situation, the Indonesian Pharmacy Association (GP Farmasi Indonesia) remains optimistic that Indonesia's pharmaceutical exports can climb in 2017.

    Read more ›

  • Indonesian Pharmaceutical Companies in Focus: Kimia Farma

    Indonesian Pharmaceutical Companies in Focus: Kimia Farma

    State-controlled pharmaceutical company Kimia Farma is expected to show steadily improving corporate earnings in the years ahead supported by Indonesia's universal healthcare scheme (in Indonesian: Jaminan Kesehatan Nasional or JKN) that was implemented by the social security agency Badan Penyelenggara Jaminan Sosial Kesehatan (BPJS) in early 2014. The scheme aims to provide all Indonesian citizens with access to a wide range of health services. Obviously, local pharmaceutical companies are in a great position to benefit from this program.

    Read more ›

  • Pharmaceutical Industry Indonesia: Plagued by Weak Rupiah

    Pharmaceutical Industry Indonesia: Plagued by Weak Rupiah

    Companies active in the pharmaceutical industry of Indonesia need to find strategies to overcome sharp rupiah depreciation. Indonesia’s pharmaceutical industry is still - to a large extent - dependent on the import of raw materials, hence a weakening rupiah raises the costs of imports thus eroding profit margins. Since May 2013, when the US Federal Reserve started to hint at monetary tightening, the US dollar has experienced bullish momentum. Between the May 2013 and July 2015, the rupiah depreciated around 37 percent against the US dollar.

    Read more ›

Associated businesses Pharmaceutical Industry